We are live on ! Find out more
KRYS icon

Krystal Biotech
KRYS

57 hedge funds and large institutions have $223M invested in Krystal Biotech in 2019 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 19 increasing their positions, 16 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

240% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 5

73% more capital invested

Capital invested by funds: $129M → $223M (+$94.1M)

27% more funds holding

Funds holding: 45 → 57 (+12)

19% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 16

3.51% more ownership

Funds ownership: 43.03% → 46.53% (+3.5%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
57
Holders Change
+12
Holders Change %
+26.67%
% of All Funds
1.23%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
17
Increased
19
Reduced
16
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$2.1M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$1.98M
3
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC)
Nebraska
+$1.46M
4
O
OrbiMed
New York
+$1.4M
5
ECM
Endurant Capital Management
California
+$1.15M

Top Sellers

Rank Fund Capital Flow
1
KCM
Knoll Capital Management
Florida
-$2.12M
2
Invesco
Invesco
Georgia
-$979K
3
NIP
Nicholas Investment Partners
California
-$466K
4
Citadel Advisors
Citadel Advisors
Florida
-$287K
5
Renaissance Technologies
Renaissance Technologies
New York
-$262K
Name Holding Trade Value Shares
Change 		Change in
Stake
PAWC
26
P.A.W. Capital
Connecticut
$1.15M -$118K -5,000 -13%
AA
27
ALPS Advisors
Colorado
$1.15M +$35.5K +1,507 +5%
Goldman Sachs
28
Goldman Sachs
New York
$1.03M +$737K +31,284 New
Renaissance Technologies
29
Renaissance Technologies
New York
$1.01M -$262K -11,100 -26%
ACH
30
ArrowMark Colorado Holdings
Colorado
$1M +$42.9K +1,821 +6%
EI
31
EAM Investors
California
$751K -$241K -10,204 -31%
Citigroup
32
Citigroup
New York
$728K +$278K +11,811 +115%
Northern Trust
33
Northern Trust
Illinois
$705K -$9.92K -421 -2%
Bank of New York Mellon
34
Bank of New York Mellon
New York
$687K -$89.8K -3,810 -15%
Acadian Asset Management
35
Acadian Asset Management
Massachusetts
$649K -$19.4K -821 -4%
TEE
36
Tibra Equities Europe
United Kingdom
$641K +$459K +19,472 New
RWM
37
Ritholtz Wealth Management
New York
$639K +$118K +5,000 +35%
ECM
38
ExodusPoint Capital Management
New York
$581K +$416K +17,648 New
Deutsche Bank
39
Deutsche Bank
Germany
$505K +$362K +15,374 New
BTS
40
BB&T Securities
Virginia
$361K – – –
Neuberger Berman Group
41
Neuberger Berman Group
New York
$313K +$224K +9,500 New
BCM
42
BlueCrest Capital Management
Jersey
$305K +$219K +9,280 New
Wells Fargo
43
Wells Fargo
California
$302K +$5.78K +245 +3%
MA
44
MYDA Advisors
New York
$296K +$212K +9,000 New
TD Asset Management
45
TD Asset Management
Ontario, Canada
$268K +$192K +8,153 New
California Public Employees Retirement System
46
California Public Employees Retirement System
California
$263K +$189K +8,000 New
State Street
47
State Street
Massachusetts
$230K +$165K +7,003 New
Squarepoint
48
Squarepoint
New York
$219K +$157K +6,651 New
JP Morgan Chase
49
JP Morgan Chase
New York
$218K +$127K +5,402 +445%
New York State Common Retirement Fund
50
New York State Common Retirement Fund
New York
$216K -$25.9K -1,097 -14%
1
2
3

KRYS Hedge Fund Activity: Q1 2019 in Review

57 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q1 2019, worth a combined $223M — up 73% from $129M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new KRYS positions and 5 closed out — a net gain of 12 holders — while 19 added to existing stakes and 16 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $2.1M. The largest seller was Knoll Capital Management, cutting an estimated $2.12M.

  • 57 institutional investors held Krystal Biotech (KRYS) as of Q1 2019, up from 45 in Q4 2018.
  • Funds reported $223M of Krystal Biotech stock for Q1 2019, up 73% quarter-over-quarter.
  • 17 funds opened new Krystal Biotech positions in Q1 2019 and 5 closed out, a net change of +12 holders.
  • The largest Krystal Biotech buyer in Q1 2019 was Millennium Management, an estimated $2.1M added.
  • The largest Krystal Biotech seller in Q1 2019 was Knoll Capital Management, an estimated $2.12M sold.

Based on aggregated 13F filings for Q1 2019.